Argenx Reports ALKIVIA Gains, Plans IMNM Filing by Year-End
The Phase 3 study met its combined-population endpoints, while argenx plans to seek FDA review for efgartigimod in IMNM by year-end.
Makkler Newsroom · Nov 7, 06:22 PM · 1 min read
Market closed· · EUR · Data may be delayed
Avg. target €996.07 (+16.6%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO